Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 3/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13377157 | 0.77 | LMNA (0.34) | TRPA1 | |
| SCHEMBL10105630 | 0.76 | PDE2A (0.34) | PDE2ATRPA1 | |
| SCHEMBL10232891 | 0.76 | ALKBH5 (0.37) | NOTUMPDE3BPDE3APDE2AS1PR1 | |
| SCHEMBL10297531 | 0.75 | AR (0.38) | AR | |
| SCHEMBL10232900 | 0.75 | RXRA (0.46) | S1PR1TRPA1SCN9A | |
| SCHEMBL10232889 | 0.73 | MPL (0.37) | AR | |
| SCHEMBL11993201 | 0.73 | ALDH1A1 (0.38) | TRPA1 | |
| SCHEMBL10624896 | 0.73 | NOTUM (0.44) | NOTUMPDE3BPDE3ARORCPDE2A | |
| SCHEMBL4547922 | 0.73 | NOTUM (0.44) | NOTUMPDE3BPDE3ARORCPDE2A | |
| SCHEMBL8291096 | 0.73 | PDE2A (0.50) | NOTUMPDE3BPDE3ARORCPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227426-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20110230465-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227426-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | HIF1AN, EGLN3, PHF20 | NOTUM 3365/4885PDE3B 914/4885PDE3A 1251/4885 |
| US-20110230465-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2E | NOTUM 2576/4885PDE3B 1758/4885PDE3A 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.